Low sensitivity of rapid tests detecting anti-CoV-2 IgG and IgM in health care workers’ serum for COVID-19 screening

Background: the sensitivity and specificity of a rapid antibody test were investigated for the screening of healthcare workers. Methods: the serum of 389 health care workers exposed to COVID-19 patients or with symptoms, were analysed. All workers underwent monthly the screening for SARS-CoV-2 with detection of viral RNA in nasopharyngeal swabs by RT-PCR. IgG antibody detection in serum was performed by Chemiluminescence Immunoassay (CLIA) and by the Rapid test (KHB diagnostic kit for SARS CoV-2 IgM/IgG antibody after a median of 7.6 weeks (25°-75° percentiles 6.6-11.5). Results: the rapid test resulted positive in 31/132 (23.5%), 16/135 (11.8%) and 0/122 cases in COVID-19 positive individuals, in those with only SARS-CoV-2 IgG antibodies and in those negative for both tests, respectively. Sensitivity was 17.6% (CI95% 13.2-22.7) and 23.5% (CI95% 16.5-31.6), and specificity was 100% (CI95% 97-100) and 100% (CI95% 97-100) considering Rapid test vs CLIA IgG or Rapid test vs SARS-CoV-2 positive RNA detection, respectively. Conclusion: the KHB Rapid test is not suitable for the screening of workers with previous COVID-19 infection.

[1]  S. Tonen-Wolyec,et al.  Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests , 2021, Journal of Virological Methods.

[2]  R. Rigolini,et al.  Anti-SARS CoV2 antibody testing in healthcare workers: comparison between rapid-cassette tests, ELISA and CLIA methods. , 2021, Journal of biological regulators and homeostatic agents.

[3]  L. Poon,et al.  Neutralizing antibody titres in SARS-CoV-2 infections , 2021, Nature communications.

[4]  C. Charpentier,et al.  Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott) , 2020, Journal of Clinical Virology.

[5]  M. Bovenzi,et al.  COVID-19 outbreak in healthcare workers in hospitals in Trieste, North-east Italy , 2020, Journal of Hospital Infection.

[6]  G. Ippolito,et al.  Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test , 2020, Journal of Clinical Virology.

[7]  M. Peeters,et al.  Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV , 2020, Journal of Clinical Virology.

[8]  A. Kouatchet,et al.  Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) , 2020, Journal of Clinical Virology.

[9]  Steven Woloshin,et al.  False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. , 2020, The New England journal of medicine.

[10]  J. Koeleman,et al.  Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital , 2020, Clinical Microbiology and Infection.

[11]  Ralph-Sydney Mboumba Bouassa,et al.  Potential pitfalls of routine SARS‐CoV‐2 serology for mass screening , 2020, Journal of medical virology.

[12]  Marie Tré-Hardy,et al.  Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody , 2020, Clinical chemistry and laboratory medicine.

[13]  Akihide Ryo,et al.  Interpreting Diagnostic Tests for SARS-CoV-2. , 2020, JAMA.

[14]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[15]  A. Petherick Developing antibody tests for SARS-CoV-2 , 2020, The Lancet.

[16]  Å. Lundkvist,et al.  Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 , 2020, Infection ecology & epidemiology.

[17]  Yuxin Chen,et al.  Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients , 2020, Emerging microbes & infections.

[18]  D. Serraino,et al.  COVID-19 infections in the Friuli Venezia Giulia Region (Northern Italy): a population-based retrospective analysis. , 2020, Epidemiologia e prevenzione.

[19]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.